Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorJiménez Masip, Alba
dc.contributor.authorAugustin Recio, Salvador
dc.contributor.authorGuerrero Moreno, Rafael
dc.contributor.authorGabriel-Medina, Pablo
dc.contributor.authorRivera-Esteban, Jesús
dc.contributor.authormuñoz, sergio
dc.contributor.authorFerrer Costa, Roser
dc.contributor.authorRODRIGUEZ-FRIAS, FRANCISCO
dc.contributor.authorPericas, Juan M
dc.date.accessioned2024-01-09T08:12:49Z
dc.date.available2024-01-09T08:12:49Z
dc.date.issued2023-12
dc.identifier.citationRivera-Esteban J, Jiménez-Masip A, Muñoz-Martínez S, Augustin S, Guerrero RA, Gabriel-Medina P, et al. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study. J Clin Med. 2023 Dec;12(23):7276.
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11351/10780
dc.descriptionMetabolic dysfunction-associated steatotic liver disease; Metabolic syndrome; Prison
dc.description.abstractBackground and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;12(23)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPresos
dc.subjectMetabolisme - Trastorns
dc.subjectCirrosi hepàtica - Factors de risc
dc.subjectEsteatosi hepàtica - Factors de risc
dc.subject.meshMetabolic Diseases
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.meshLiver Cirrhosis
dc.subject.meshRisk Factors
dc.subject.meshPrisoners
dc.titlePrevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm12237276
dc.subject.decsenfermedades metabólicas
dc.subject.decsesteatosis hepática no alcohólica
dc.subject.decscirrosis hepática
dc.subject.decsfactores de riesgo
dc.subject.decsprisioneros
dc.relation.publishversionhttps://doi.org/10.3390/jcm12237276
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rivera-Esteban J, Jiménez-Masip A] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Muñoz-Martínez S, Augustin S] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Guerrero RA] Prison Health Program, Catalan Institute of Health, Barcelona, Spain. [Gabriel-Medina P, Ferrer-Costa R, Rodríguez-Frías F] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pericàs JM] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centros de Investigación Biomédica en Red, Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain
dc.identifier.pmid38068330
dc.identifier.wos001116132600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record